Download Full eBooks in PDF
Drug Industry Act Of 1962 Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Drug Industry Act Of 1962 book. This book definitely worth reading, it is an incredibly well-written.
Author : United States. Congress. House. Committee on Interstate and Foreign Commerce
Publisher : Unknown
Page : 724 pages
File Size : 55,7 Mb
Release : 1962
Category : Cosmetics
ISBN : MINN:31951D03518354N
Author : United States. Congress. House. Committee on Interstate and Foreign Commerce
Publisher : Unknown
Page : 734 pages
File Size : 51,8 Mb
Release : 1962
Category : Cosmetics
ISBN : LOC:00089184836
Considers the following bills to amend the Federal Food, Drug, and Cosmetic Act. H.R. 11581, the Drug and Factory Inspection Amendments of 1962, to require manufacturers to follow certain research, production and marketing safety procedures. H.R. 11582, the Cosmetics and Therapeutic Devices Amendments of 1962, to require safety certification for cosmetics and medical devices; to require labeling on containers containing hazardous substances; and to strengthen controls on food and animal feed additives.
Author : Eastland subm. the report together with individual views (to accompany S. 1552)
Publisher : Unknown
Page : 63 pages
File Size : 40,9 Mb
Release : 1962
Category : Electronic
ISBN : OCLC:254714051
Author : Sam Peltzman
Publisher : Unknown
Page : 132 pages
File Size : 52,8 Mb
Release : 1974
Category : Law
ISBN : UOM:39015010677964
"Measure[s] the net benefits produced by the 1962 amendments to the Food, drug, and cosmetic act." Includes bibliographical references.
Author : United States. Dept. of Health, Education, and Welfare. Review Panel on New Drug Regulation
Publisher : Unknown
Page : 216 pages
File Size : 49,6 Mb
Release : 1977
Category : Electronic
ISBN : IND:30000043835846
Author : Peter Temin
Publisher : Unknown
Page : 296 pages
File Size : 52,8 Mb
Release : 1980
Category : Business & Economics
ISBN : UOM:39015004345883
A history of the federal regulation of the sale and use of medicinal drugs throughout the twentieth century examines the reasons for and impact of Federal Food and Drug Administration.
Author : United States. Congress. House. Interstate and Foreign Commerce
Publisher : Unknown
Page : 732 pages
File Size : 49,8 Mb
Release : 1962
Category : Electronic
ISBN : STANFORD:36105045424343
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 51,8 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : Institute of Medicine,Committee on Technological Innovation in Medicine
Publisher : National Academies Press
Page : 225 pages
File Size : 45,6 Mb
Release : 1991-02-01
Category : Medical
ISBN : 9780309044912
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author : P. Roy Vagelos,Louis Galambos
Publisher : Cambridge University Press
Page : 326 pages
File Size : 43,7 Mb
Release : 2004-01-05
Category : Biography & Autobiography
ISBN : 0521662958
This book traces the careers of Roy Vagelos, who eventually became the CEO of Merck and Co., Inc.
Author : Upton Sinclair
Publisher : Xist Publishing
Page : 452 pages
File Size : 46,9 Mb
Release : 2016-04-20
Category : Fiction
ISBN : 9781681959757
The Jungle by Upton Sinclair from Coterie Classics All Coterie Classics have been formatted for ereaders and devices and include a bonus link to the free audio book. “The great corporation which employed you lied to you, and lied to the whole country—from top to bottom it was nothing but one gigantic lie.” ― Upton Sinclair, The Jungle Upton’s Sinclair’s classic novel changed the American relationship with food and used its illumination of the horrors of the meat packing industry to indict the evil of American society.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
Publisher : National Academies Press
Page : 483 pages
File Size : 55,9 Mb
Release : 2017-09-28
Category : Medical
ISBN : 9780309459570
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : Institute of Medicine,Board on Population Health and Public Health Practice,Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process
Publisher : National Academies Press
Page : 141 pages
File Size : 42,9 Mb
Release : 2010-10-04
Category : Medical
ISBN : 9780309162906
The Food and Drug Administration (FDA) is responsible for assuring that medical devices are safe and effective before they go on the market. As part of its assessment of FDA's premarket clearance process for medical devices, the IOM held a workshop June 14-15 to discuss how to best balance patient safety and technological innovation. This document summarizes the workshop.
Author : Henry G. Grabowski,John Mitcham Vernon
Publisher : A E I Press
Page : 88 pages
File Size : 51,9 Mb
Release : 1983
Category : Law
ISBN : UOM:39015004026640
The authors review the empirical evidence concerning the Food and Drug Administration's effect on the rate of innovation, the delays in introducing new drugs, and the profitability of pharmaceutical research.
Author : Institute of Medicine,Committee to Study the Use of Advisory Committees
Publisher : National Academies Press
Page : 239 pages
File Size : 54,9 Mb
Release : 1992-02-01
Category : Medical
ISBN : 9780309048378
Like many other agencies of the federal government, the Food and Drug Administration (FDA) relies extensively on external advisory committees for independent scientific and technical advice. Recognizing that the existing advisory committee system is essentially sound, this volume recommends ways of enhancing the use of these committees in the evaluation of drugs, biological materials, and medical devices; strengthening the agency's management of the system; and increasing the accountability of the system to the public. In doing so, it examines and makes recommendations on such issues as the recruitment of committee members, the FDA's management of financial conflict of interest and intellectual bias among members, and the operations and management of the advisory committee system.